+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

Serotonin 1B receptor agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Serotonin 1B receptor agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Histamine H1 receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Histamine H1 receptor antagonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
T type calcium channel antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

T type calcium channel antagonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
TrkC receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

TrkC receptor antagonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Dopamine D1 receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Dopamine D1 receptor antagonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Cannabinoid receptor CB1 inverse agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Cannabinoid receptor CB1 inverse agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
Japan Alzheimer's Disease - Epidemiology Forecast - 2032 - Product Thumbnail Image

Japan Alzheimer's Disease - Epidemiology Forecast - 2032

  • Report
  • January 2024
  • 100 Pages
  • Japan
From
From
LRRK2 Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

LRRK2 Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
GABA A receptor agonist - Pipeline Insight, 2024 - Product Thumbnail Image

GABA A receptor agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 100 Pages
  • Global
From
Dopamine D2 receptor antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Dopamine D2 receptor antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
ZEPOSIA Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

ZEPOSIA Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
United States AUSTEDO Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

United States AUSTEDO Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • United States
From
Ingrezza Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Ingrezza Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
CAEL-101 Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

CAEL-101 Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
Melflufen Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Melflufen Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
EXSERVAN Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

EXSERVAN Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • September 2022
  • 30 Pages
  • Global
From
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more